Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
INC Research
DB Schenker
Farma Force
Latest News
PBS just 88 cents per person, per day
Government spending on the PBS and RPBS has dropped to just 88 cents per person per day since the introduction of expanded and accelerated price disclosure says the latest PBS Scorecard.
Fix IP mess now MA tells govt
Medicines Australia CEO Tim James is calling on the government to strengthen Australia's intellectual property system, saying recent policies have undermined confidence and stability.
Tamper worry hits generic oxycodone
Non-tamper resistant generics of oxycodone set to list on the PBS next month will be substitutable for tamper resistant OxyContin despite an attempt by Mundipharma to persuade the PBAC otherwise.
GPs' dispensing call escalates turf war
The Pharmacy Guild has described a call by doctor groups to expand GP dispensing rights as neither serious nor constructive.
Gilead Aust boosts research grants
Gilead has announced the winners of six patient care research grants in HIV and viral hepatitis and said it will boost funding for the Gilead Australia Fellowship by close to $100,000 next year.
Earlier
PBS $1.4bn ahead of last year
At $9.39 billion, PBS outlays are now $1.45 billion ahead of where they were at this time last year, the latest figures released by the government show.
Novartis deal up to GSK shareholders
GSK has asked shareholders to vote at a meeting on December 18 to approve its proposed deal with Novartis under which the two pharma giants will trade more than US$20 billion in assets.
Zytiga access eased for some patients
Changes to the PBS restrictions of Janssen's prostate cancer drug Zytiga will open up the treatment to more patients with advanced prostate cancer come December 1.
Trans-Tasman patents given Reps nod
The House of Reps has passed legislation that will allow for single application and examination processes for applying for patents in Australia and New Zealand.
STA's Iclusig wins TGA appoval
Specialised Therapeutics Australia (STA) will be hoping it enjoys similar success at the PBAC as it's had at the TGA, with the latter giving Iclusig marketing approval early this week.
Pharmac changes funding framework
Pharmac has revealed that it will be changing the way it makes funding decisions from next year, including explicit acknowledgement of the impact of its decisions on Maori health needs and the wider society.
AbbVie adds Aust to hep C list
AbbVie has confirmed it has applied for regulatory approval in Australia for new hep C treatment Exviera and Viekirax, which has just won an EMA approval recommendation.
Aust OTC sales have strong quarter
Sales of OTC pharmacy products have become a $5 billion industry in Australia and grew at five per cent over the past 12 months, with the last quarter delivering even stronger growth, up 9.5 per cent compared to a year ago, according to Nielsen research.
DHL boosts cooled transport
Temperature controlled transport of general pharmaceuticals has been picked as one of the key issues for big pharma in the next few years, with DHL ready to tap into it from 2015.
A third of antibiotics 'inappropriate'
Of the 1,174 antimicrobial prescriptions given to hospitalised children, some 34 per cent may be inappropriate, with the highest rate among surgical patients.
Rubber stamp regulation on the cards
The Sansom review of medicines regulation has released a discussion paper that includes the possibility of Australia following decisions made by 'trusted regulators' overseas.
Stage set for final Code battle
Final ACCC submissions on the MA Code show the battle is now over a proposed 12 month moratorium on disclosure, continued event reporting and naming of drugs connected to reported events.
TGA changes spooked NZ says Labor
The Labor Party has flagged concern that last week's abandonment of the ANZTPA was caused by disquiet in NZ over recent regulatory change in Australia.
ASMI calls for switch taskforce
As Australia falls behind other countries in script to OTC switching ASMI is calling for a 'switch taskforce' to be formed to revive flagging industry and government interest.
Trillion-dollar meds sales forecast
Global spending on medicines is forecast to reach nearly US$1.3 trillion by 2018, with higher spending on specialty medicines, particularly in developed markets, contributing to the growth.
'Health destination' boosts pharmacies
The PSA's Health Destination Pilot is showing that successful pharmacists are able to "buck the trend" of falling revenues, seeing average growth of more than 12 per cent.
Sanofi names Ebola response czar
Sanofi has appointed its chief scientific officer, Gary Nabel, as the company's Ebola response coordinator.
Last days for Pfizer's Celebrex
One of Pfizer's best-known medicines, pain-killer Celebrex will face generic competition for the first time on the PBS from December 1 as will GSK's Panadol Osteo.
Ministers call time on ANZTPA
The TGA and Medsafe will be going their own ways as the health ministers of Australia and NZ declare an official end to the second attempt to create a joint regulator.
Symbion opens $40m logistics hub
Symbion MD Patrick Davies claims its new state-of-the art $40m distribution centre in Melbourne is the most advanced pharmaceutical facility in the world today.
Bayer's Sargent back to lead ASMI
Mark Sargent, GM consumer care ANZ at Bayer, has been re-elected as ASMI president, marking his third year in the role.
Sigma repudiates competition panel
Wholesaler Sigma has come out again in support of pharmacy, rejecting the Competition Policy Review panel's recommendation to remove ownership and location rules.
Cost of drug development skyrockets
Getting a new prescription medicine from bench to market approval now costs over US$2.5 billion, more than double the cost in 2003 says a study of over 100 drugs from 10 pharmacos.
Govt missing billions in switch savings
Australian drug regulation is too focused on protecting a few potential drug misusers, preventing the government from realising billions in savings that could come from more down-scheduling.
AFT beats GSK in TM stoush
GSK's Panadol Osteo franchise is under assault on several fronts but this time it has lost the fight against AFT Pharmaceuticals over an application to trademark 'Paracetamol Osteo-Tab'.
Asthma meds too expensive
Asthma expert Professor Guy Marks says the high cost of daily preventer medications in Australia makes them unaffordable for many sufferers, leaving them liable to attacks.
Vytorin efficacy finally proven
MSD's Vytorin has been shown to lower the risk of future cardiovascular problems in high-risk patients with acute coronary syndrome.
Open Forum
Community pharmacy won't be a theory victim says PM
Prime Minister Tony Abbott told the Pharmacy Guild's annual dinner he is a strong supporter of community pharmacy and 'won't promote theory over practice' when it comes to managing the health budget. Here's what he said in full.
Pipeline Monitor
Novartis scores in psoriasis
Novartis' new first-in-class psoriasis treatment Cosentyx has been recommended for approval in Europe while BI continues to do battle with Roche in bringing new IPF drugs to market.
Approvals Action
Lantus biosimilar threatens $140m market
Abasria Eli Lilly's biosimilar competitor for Sanofi's Lantus has been approved by the TGA, threatening the $140 million market held by the leading diabetes product.
Special Report
Who's growing fastest on the PBS?
At the end of Q2 14-15, two companies stood out among the top PBS earners for growth that outpaces the average, thanks to highly successful drug launches in 2012 and 2013 but change could be afoot in the next 12 months.
Open Forum
Is switch a turn-off for Aust industry?
The week's annual ASMI conference heard a lot about how Australia is lagging when it comes to moving tried and true treatments from the script pad to the consumer's shopping list but can the regulatory blockages be cleared?
Working Life
Gender equality: why Merck Serono is a winner
Merck Serono's appearance on the inaugural Employer of Choice for Gender Equality list is not by chance, gender equality is something the company 'lives and breathes' says MD Andre Musto.
FREE Content
Events & Conferences
SEARCH NOW
Pharma in Focus Jobs
Ascott Sales
Veeva